Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | STS | P08842 | 3/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 4/20 | 0.40 |
| ▸ | FNTB | P49356 | 4/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30623464 | 0.81 | MEN1 (0.45) | MEN1KMT2ASTSCNR1FNTA | |
| SCHEMBL25358733 | 0.81 | MEN1 (0.45) | MEN1KMT2ASTSCNR1FNTA | |
| SCHEMBL25357977 | 0.80 | MEN1 (0.44) | MEN1KMT2ASTSCNR1FNTA | |
| SCHEMBL25359658 | 0.80 | MEN1 (0.45) | MEN1KMT2ASTSFNTAFNTB | |
| SCHEMBL26013316 | 0.80 | MEN1 (0.43) | MEN1KMT2ASTSCNR1FNTA | |
| SCHEMBL30623422 | 0.80 | MC4R (0.48) | MEN1KMT2ASTSCNR1FNTA | |
| SCHEMBL25359666 | 0.80 | MC4R (0.48) | MEN1KMT2ASTSCNR1FNTA | |
| SCHEMBL25362925 | 0.79 | POLB (0.36) | MEN1KMT2ASTSSMN1; SMN2MC4R | |
| SCHEMBL2159558 | 0.78 | AVPR1A (0.49) | MEN1KMT2ASTS | |
| SCHEMBL1812199 | 0.76 | GPR119 (0.37) | STSSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195483-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2025-06-19 | — | — | US | disclosed |
| EP-4476207-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195483-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, SAAL1 | MEN1 2419/4885KMT2A 4614/4885STS 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.